One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/s2152-2650(21)02087-5
Copy DOI
Export
Save
Share
Cite Publication Date: Oct 1, 2021 | |
 Citations: 5 |
Affiliation: Emory University, Dana-Farber Cancer Institute, University College London Hospitals NHS Foundation Trust, University of Pennsylvania, Mayo Clinic, Institut Català d'Oncologia, University Hospital Würzburg, University of Leeds, University of Maryland Medical Center, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Hackensack University Medical Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), Vrije Universiteit Amsterdam
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
